Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
作者信息
Chan Wei Yee, Zhu Catherine, Sanchez Emilie, Gupta Rajeev, Fielding Adele K, Khwaja Asim, Payne Elspeth M, O'Nions Jenny
机构信息
Department of Haematology, University College London NHS Foundation Trust, London, UK.
UCL Cancer Institute, University College London, London, UK.
出版信息
Br J Haematol. 2022 Aug;198(3):478-481. doi: 10.1111/bjh.18248. Epub 2022 May 19.
Abstract
摘要
相似文献
1
Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.接受积极抗癌治疗的急性髓系白血病和高危骨髓增生异常综合征患者对SARS-CoV-2疫苗接种的抗体反应。
Br J Haematol. 2022 Aug;198(3):478-481. doi: 10.1111/bjh.18248. Epub 2022 May 19.
2
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.mRNA 新冠疫苗在骨髓恶性肿瘤患者中的体液免疫反应。
Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14.
3
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.新冠病毒mRNA疫苗在急性髓系白血病和骨髓增生异常综合征患者中的免疫原性
Leuk Lymphoma. 2023 Mar;64(3):662-670. doi: 10.1080/10428194.2022.2131414. Epub 2022 Oct 25.
4
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.COVID-19 疫苗接种后 T 细胞应答缺陷与急性髓系白血病和骨髓增生异常综合征。
Br J Haematol. 2023 Aug;202(3):498-503. doi: 10.1111/bjh.18894. Epub 2023 Jun 12.
5
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.健康受试者对 mRNA COVID-19 疫苗的抗体反应差异。
Microbiol Spectr. 2021 Sep 3;9(1):e0034121. doi: 10.1128/Spectrum.00341-21. Epub 2021 Aug 4.
6
Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.炎症性肠病患者接种 SARS-CoV-2 疫苗后抗体生成受损：一项泛希腊注册研究的结果。
Inflamm Bowel Dis. 2023 Feb 1;29(2):228-237. doi: 10.1093/ibd/izac068.
7
Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders.肌肉疾病患者肌内注射 SARS-CoV-2 mRNA 疫苗的免疫原性。
Front Immunol. 2023 Feb 7;14:1103196. doi: 10.3389/fimmu.2023.1103196. eCollection 2023.
8
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.一剂 BNT162b2 mRNA 疫苗可诱导慢性髓性白血病患者产生针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的中和抗体和多功能 T 细胞反应。
Br J Haematol. 2021 Sep;194(6):999-1006. doi: 10.1111/bjh.17568. Epub 2021 Jun 3.
9
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.SARS-CoV-2 刺突蛋白抗体疫苗反应与癌症患者感染严重程度的关联：全国 COVID 癌症横断面评估。
JAMA Oncol. 2023 Feb 1;9(2):188-196. doi: 10.1001/jamaoncol.2022.5974.
10
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.癌症治疗患者接种 COVID-19 疫苗后的抗体和 T 细胞反应。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004766.
引用本文的文献
1
Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.mRNA 疫苗加强针在血液系统恶性肿瘤患者中的效果。
Cancer Med. 2023 Aug;12(16):16881-16888. doi: 10.1002/cam4.6314. Epub 2023 Jul 6.
本文引用的文献
1
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.mRNA 新冠疫苗在骨髓恶性肿瘤患者中的体液免疫反应。
Br J Haematol. 2022 Jun;197(6):691-696. doi: 10.1111/bjh.18138. Epub 2022 Mar 14.
2
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.血液恶性肿瘤患者中疾病和治疗特异性对 COVID-19 疫苗接种后体液免疫应答的影响。
Blood Cancer Discov. 2021 Sep 13;2(6):568-576. doi: 10.1158/2643-3230.BCD-21-0139. eCollection 2021 Nov.
3
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.接受针对新冠病毒病全剂量疫苗接种的B细胞恶性肿瘤患者血清阳性率低且中和率未达最佳水平。
Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.
4
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.血液恶性肿瘤患者对 SARS-CoV-2 疫苗的免疫原性较弱。
Blood Cancer J. 2021 Aug 10;11(8):142. doi: 10.1038/s41408-021-00534-z.
5
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.血液系统恶性肿瘤患者对SARS-CoV-2疫苗的抗体反应。
Cancer Cell. 2021 Aug 9;39(8):1031-1033. doi: 10.1016/j.ccell.2021.07.012. Epub 2021 Jul 22.
6
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
7
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.BNT162b2 COVID-19 疫苗在血液恶性肿瘤患者中的有效性显著降低。
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
8
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.既往自然感染人群中新型冠状病毒2型（SARS-CoV-2）的抗体反应
N Engl J Med. 2021 Jul 1;385(1):90-92. doi: 10.1056/NEJMc2103825. Epub 2021 Apr 14.
9
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对单剂量BNT162b2疫苗体液和T细胞反应的影响
Lancet. 2021 Mar 27;397(10280):1178-1181. doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.
Zotero 插件